AtriCure, Inc. Files Q3 2024 10-Q Report
Ticker: ATRC · Form: 10-Q · Filed: Oct 30, 2024 · CIK: 1323885
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
**AtriCure Q3 2024 10-Q filed. Financials and ops details inside.**
AI Summary
AtriCure, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2024. Specific financial figures and operational highlights are presented within the report.
Why It Matters
This filing provides investors and analysts with the latest financial and operational data for AtriCure, Inc., crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new risks highlighted.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2024-10-30 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- AtriCure, Inc. (company) — Filer of the 10-Q report
- 2024-09-30 (date) — End of the reporting period
- 2024-10-30 (date) — Date of filing
- 7555 INNOVATION WAY, MASON, OH 45040 (address) — Company's business and mailing address
FAQ
What is the total revenue for the nine months ended September 30, 2024?
The filing does not explicitly state the total revenue for the nine months ended September 30, 2024, as this is a header file and not the full 10-Q document.
What was AtriCure's net income for the third quarter of 2024?
The net income for the third quarter of 2024 is not provided in this header document.
Are there any significant changes in AtriCure's debt structure reported in this filing?
This header document does not contain details on debt structure changes.
What is the company's fiscal year end date?
AtriCure, Inc.'s fiscal year ends on December 31.
What is the SIC code for AtriCure, Inc.?
The Standard Industrial Classification (SIC) code for AtriCure, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 4,605 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2024-10-30 11:49:04
Filing Documents
- atrc-20240930.htm (10-Q) — 894KB
- exhibit311-930202410xq.htm (EX-31.1) — 10KB
- exhibit312-930202410xq.htm (EX-31.2) — 10KB
- exhibit321-930202410xq.htm (EX-32.1) — 6KB
- exhibit322-930202410xq.htm (EX-32.2) — 6KB
- atrc-20240930_g1.jpg (GRAPHIC) — 21KB
- atrc-20240930_g2.jpg (GRAPHIC) — 22KB
- atrc-20240930_g3.jpg (GRAPHIC) — 20KB
- 0001323885-24-000117.txt ( ) — 5874KB
- atrc-20240930.xsd (EX-101.SCH) — 36KB
- atrc-20240930_cal.xml (EX-101.CAL) — 74KB
- atrc-20240930_def.xml (EX-101.DEF) — 130KB
- atrc-20240930_lab.xml (EX-101.LAB) — 549KB
- atrc-20240930_pre.xml (EX-101.PRE) — 359KB
- atrc-20240930_htm.xml (XML) — 815KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.
Controls and Procedures
Controls and Procedures 23
OTHER INFORMATION
PART II. OTHER INFORMATION 23 Item 1.
Legal Proceedings
Legal Proceedings 23 Item 1A.
Other Information
Item 5. Other Information 23 Item 6. Exhibits 24
Signatures
Signatures 25 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Per Share Amounts) (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 130,335 $ 84,310 Short-term investments — 52,975 Accounts receivable, less allowance for credit losses of $ 400 and $ 500 54,909 52,501 Inventories 76,546 67,897 Prepaid and other current assets 7,496 8,563 Total current assets 269,286 266,246 Property and equipment, net 43,537 42,435 Operating lease right-of-use assets 6,100 4,324 Intangible assets, net 58,352 63,986 Goodwill 234,781 234,781 Other noncurrent assets 3,012 2,160 Total Assets $ 615,068 $ 613,932 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 31,736 $ 27,354 Accrued liabilities 39,980 44,682 Current lease liabilities 2,715 2,533 Total current liabilities 74,431 74,569 Long-term debt 61,865 60,593 Finance and operating lease liabilities 12,548 11,368 Other noncurrent liabilities 1,203 1,234 Total Liabilities 150,047 147,764 Commitments and contingencies (Note 9) Stockholders' Equity: Common stock, $ 0.001 par value, 90,000 shares authorized and 48,748 and 47,526 issued and outstanding 49 48 Additional paid-in capital 851,306 824,170 Accumulated other comprehensive loss ( 147 ) ( 993 ) Accumulated deficit ( 386,187 ) ( 357,057 ) Total Stockholders' Equity 465,021 466,168 Total Liabilities and Stockholders' Equity $ 615,068 $ 613,932 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ 115,910 $ 98,290 $ 341,030 $ 292,702 Cost of revenue 29,117 24,421 86,125 72,147 Gross profit 86,793 73,869 254,9